Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers

Molecular Cancer

Research

B. Anthony Bell¹  Greg A. Fellows¹  John R. Griffiths²  M. Wilson³  Franklyn A. Howe⁴  Alan J. Wright⁴ 

[1] Academic Neurosurgery Unit, St George's, University of London, London, UK;Cancer Research UK Cambridge Research Institute, Cambridge, UK;Cancer Sciences, University of Birmingham, Birmingham, UK;Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK;Cardiac and Vascular Sciences, St George's, University of London, London, UK;

关键词: Nuclear Magnetic Resonance;    Brain Tumour;    Meningioma;    Astrocytoma;    Metabolite Concentration;   

DOI  :  10.1186/1476-4598-9-66

 received in 2009-10-21, accepted in 2010-03-23,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundHigh-resolution magic angle spinning (HRMAS) NMR spectroscopy allows detailed metabolic analysis of whole biopsy samples for investigating tumour biology and tumour classification. Accurate biochemical assignment of small molecule metabolites that are "NMR visible" will improve our interpretation of HRMAS data and the translation of NMR tumour biomarkers to in-vivo studies.Results1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with 8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour (astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas). Differences in concentration of 20 of these metabolites were statistically significant between these brain tumour types. During the course of an extended 2D data acquisition the HRMAS technique itself affects sample analysis: glycine, glutathione and glycerophosphocholine all showed small concentration changes; analysis of the sample after HRMAS indicated structural damage that may affect subsequent histopathological analysis.ConclusionsA number of small molecule metabolites have been identified as potential biomarkers of tumour type that may enable development of more selective in-vivo1H NMR acquisition methods for diagnosis and prognosis of brain tumours.

【 授权许可】

CC BY   
© Wright et al; licensee BioMed Central Ltd. 2010